BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32641598)

  • 41. Mantle Cell Lymphoma With Hodgkin and Reed-Sternberg Cells: Review With Illustrative Case.
    Kramer S; Uppal G; Wang ZX; Gong JZ
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):8-14. PubMed ID: 28549034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas.
    Blakolmer K; Vesely M; Kummer JA; Jurecka W; Mannhalter C; Chott A
    Mod Pathol; 2000 Jul; 13(7):766-72. PubMed ID: 10912936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma.
    Hoeller S; Zihler D; Zlobec I; Obermann EC; Pileri SA; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jan; 56(2):217-28. PubMed ID: 20102401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases.
    Loo EY; Medeiros LJ; Aladily TN; Hoehn D; Kanagal-Shamanna R; Young KH; Lin P; Bueso-Ramos CE; Manning JT; Patel K; Thomazy V; Brynes RK; Goswami M; Fayad LE; Miranda RN
    Am J Surg Pathol; 2013 Aug; 37(8):1290-7. PubMed ID: 23774171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma.
    Kim HJ; Kim HK; Park G; Min SK; Cha HJ; Lee H; Choi SJ; Na HY; Choe JY; Kim JE
    Diagn Pathol; 2019 Dec; 14(1):133. PubMed ID: 31831043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma.
    Bohle V; Döring C; Hansmann ML; Küppers R
    Leukemia; 2013 Mar; 27(3):671-9. PubMed ID: 23174882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
    Vandenberghe P; Wlodarska I; Tousseyn T; Dehaspe L; Dierickx D; Verheecke M; Uyttebroeck A; Bechter O; Delforge M; Vandecaveye V; Brison N; Verhoef GE; Legius E; Amant F; Vermeesch JR
    Lancet Haematol; 2015 Feb; 2(2):e55-65. PubMed ID: 26687610
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
    Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
    Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mediastinal lymphomas].
    Rauthe S; Rosenwald A
    Pathologe; 2016 Sep; 37(5):457-64. PubMed ID: 27507160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathological Study of 30 Cases of Peripheral T-cell Lymphoma with Hodgkin and Reed-Sternberg-like B-cells from Japan.
    Eladl AE; Satou A; Elsayed AA; Suzuki Y; Kato S; Asano N; Nakamura S
    Am J Surg Pathol; 2017 Apr; 41(4):506-516. PubMed ID: 28125450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Follicular Hodgkin's disease.
    Ashton-Key M; Thorpe PA; Allen JP; Isaacson PG
    Am J Surg Pathol; 1995 Nov; 19(11):1294-9. PubMed ID: 7573692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
    Lennerz JK; Hoffmann K; Bubolz AM; Lessel D; Welke C; Rüther N; Viardot A; Möller P
    Oncotarget; 2015 Oct; 6(30):29097-110. PubMed ID: 26336985
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
    Huang R; Zhang X; Sophia S; Min Z; Liu X
    Anticancer Drugs; 2018 Apr; 29(4):364-370. PubMed ID: 29481474
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Classical Hodgkin Lymphoma With Aberrant CD8 Expression: A Clinicopathologic Study of Five Cases.
    Mirzamani N; Zhang X; Brody J; Spitzer SG; Sen F; Hsu P
    Int J Surg Pathol; 2019 Apr; 27(2):166-173. PubMed ID: 30058423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hodgkin disease with subsequent transformation to CD30 positive non-hodgkin lymphoma in six patients.
    Mori N; Watanabe K; Yamashita Y; Nakayama A; Yatabe Y; Narita M; Kobayashi T; Hasegawa Y; Kojima H; Nagasawa T
    Cancer; 1999 Feb; 85(4):970-9. PubMed ID: 10091777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Expression of fragile histidine triad (FHIT) protein and its significance in diagnosing classical Hodgkin lymphoma].
    Zhao P; Lü YL; Zhong M; Chen LH; Pu XL
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):289-91. PubMed ID: 16777001
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Composite recurrent hodgkin lymphoma and diffuse large B-cell lymphoma: one clone, two faces.
    Huang Q; Wilczynski SP; Chang KL; Weiss LM
    Am J Clin Pathol; 2006 Aug; 126(2):222-9. PubMed ID: 16891197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of mast cells in fibrosis of classical Hodgkin lymphoma.
    Nakayama S; Yokote T; Hiraoka N; Nishiwaki U; Hanafusa T; Nishimura Y; Tsuji M
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):603-611. PubMed ID: 27095287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinicopathological study of nm23-H1 expression in classical Hodgkin's lymphoma.
    Niitsu N; Nakamine H; Okamoto M; Tamaru JI; Hirano M
    Ann Oncol; 2008 Nov; 19(11):1941-6. PubMed ID: 18647967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.